Fibrosis Stocks
Biopharmaceutical firms in this space develop small molecules and biologics designed to arrest or reverse the pathological accumulation of excess extracellular matrix components that lead to organ scarring and systemic dysfunction.
As of Oct 23, 2026, Fibrosis has 17 US-listed companies worth $14.8B combined. The median member moved -1.8% over the past week; IVA led at +26.2% and CMMB trailed at -18.6%.
Companies in Fibrosis
- MDGL – Madrigal Pharmaceuticals Inc, $10B
- DMRA – Damora Therapeutics, Inc., $1.2B
- IVA – Inventiva Sa, $770M
- GYRE – Gyre Therapeutics Inc., $717M
- SGMT – Sagimet Biosciences Inc. Series A Common Stock, $633M
- AGMB – AgomAb Therapeutics NV American Depositary Shares, $422M
- GALT – Galectin Therapeutics Inc, $374M
- PALI – Palisade Bio Inc, $251M
- VCRE – Vicore Pharma Holding AB American Depositary Shares, $244M
- MNOV – MediciNova Inc, $73.8M
- PLRX – Pliant Therapeutics Inc, $54.7M
- RNTX – Rein Therapeutics Inc, $54.2M
- TVRD – Tvardi Therapeutics, Inc., $13.7M
- CMMB – Chemomab Therapeutics Ltd DRC, $8.4M
- GLMD – Galmed Pharmaceuticals Ltd, $4.9M
- GRI – GRI Bio Inc., $4.2M
- OCEA – Ocean Biomedical Inc., $185,892